Alejo Rodriguez-Vida, Pablo Maroto, Albert Font, Cristina Martin, Begoña Mellado, Alex Corbera, Mayra Orrillo, Oscar Reig, Rosa Querol, Alejandro Rios-Hoyo, Laia Cano, Judith Alonso, Gemma Martinez, Susana Galtes, Alvaro Taus, Maria Martinez-Garcia, Nuria Juanpere, Oscar Juan, Joaquim Bellmunt
BACKGROUND: Single-agent PD-1/PD-L1 inhibitors have shown limited efficacy in unselected mCRPC. The evidence of a survival benefit with sipuleucel-T and ipilimumab, provides a rationale to study further increasing immunogenicity in mCRPC through combinations. METHODS: Safety and efficacy avelumab plus carboplatin was investigated in a single-arm Phase Ib study in mCRPC, progressing to at least one taxane and one androgen-receptor inhibitor. The primary endpoint was safety...
October 26, 2022: British Journal of Cancer